Molecular monitoring of Plasmodium vivax infection after radical treatment in Southeastern Iran

Iranian Journal of Arthropod-Borne Diseases

Volumn 4, Issue 1, 2010, Pages 24-30

  Nateghpour, M ^a   Ayazian Mavi, S ^a   Keshavarz, H ^a   Rezaei, S ^a   Abedi, F ^b   Edrissian, G H ^a   Raeisi, A ^c  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b HORMOZGAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c MINISTRY OF HEALTH AND MEDICAL EDUCATION   (Iran)

Author keywords

Iran; P. vivax; pvMSP1; Re infection; Recrudescence; Relapse

Indexed keywords

EID: 79957827198     PISSN: 17357179     EISSN: 20082517     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Adak T, Sharma VP, Orlov VS (1998) Studies on the Plasmodium vivax relapse pattern in Delhi, India. Am J Trop Med Hyg. 59: 175-179.
2. CDC of Ministry of Health & Medical Education (2008) Annual report of malaria cases. I.R.Iran
3. Chen N, Aullif A, Rieckmann K, Gatton M, Cheng Q (2007) Relapses of Plasmodium vivax infection result from clonal hypnozoites activated at predetermined intervals. J Infect Dis 195: 934-941.
4. Coatney GR, Cooper WC, Young MD (1950) Studies in human malaria.xxx. A summary of 204 sporozoiteinduced infection with the Chesson strain of Plasmodium vivax. Journal of National Malaria Society. 9: 381-396.
5. Collins WE, Jeffery GM (1996) Primaquine resistance in Plasmodium vivax. Am J Trop Med Hyg. 55: 243-249.
6. Collins WE, Sullivan JS, Morris, CL, Galland GG, Richardson B (1996) Observations on biological nature of Plasmodium vivax sporozoites. J Parasitol. 82: 216-219.
7. Craig AA, Kain KC (1996) Molecular analysis of strains of Plasmodium vivax from paired primary and relapse infection. J Infect Dis. 174: 373-379.
8. Gogtay NJ, Desai S, Kadam VS, Kamtekar KD, Dalvi SS, Kshirsagar NA (2000) Relapse pattern of Plasmodium vivax in Mumbai: a study of 283 cases of vivax malaria. J Assoc Phys India. 48: 1085- 1086.
9. Haghdoost A, Mazhari SH, Bahaadini K (2006) Estimating the relapse risk of Plasmodium vivax in Iran under national chemotherapy scheme using a novel method. J Vect Borne Dis. 43: 168- 172.
10. Hay SI, Guerra CA, Tatem AJ, Noor AM, Snow RW (2004) The global distribution and population at risk of malaria: past, present, and future. Lancet Infect Dis. 4: 327-336.
11. Imwong M, Snounou G, Pukrittayakamee S, Tanomsing N, Kim JR, Nandy A, et al. (2007) Relapse of Plasmodium vivax infection usually result from activation of heterologous hypnozoites. J Infect Dis. 195: 927-933.
12. Kirchgatter K, del Portillo HA (1998) Molecular analysis of Plasmodium vivax relapses using the MSP1 molecule as a genetic marker. J Infect Dis. 177: 511-515.
13. Koepfli C, Mueller I, Marfurt J, Goroti M, Sie A, Oa O, Genton B, Beck HP Fleger I (2009) Evaluation of Plasmodium vivax Genotyping Markers for Molecular Monitoring in Clinical Trials. J Infect Dis. 199: 1074-1080.
14. Krotoski WA (1985) Discovery of the hypnozoite and a new theory of malarial relapse. Trans R Soc Trop Med Hyg. 79: 1-11.
15. Leslie T, Rab MA, Ahmadzai H, Durrani N, Fayaz M, Kolaczinski J, Rowland M (2004) Compliance with 14-day primaquine therapy for radical cure of vivax malaria-a randomized placebo-controlled trial comparing unsupervised with supervised treatment. Trans R Soc Trop Med Hyg. 98:168-173.
16. Leslie T, Mayan I, Mohammed N, Erasmus P, Kolackzinski J, Whitty CJM, Rowland M (2008) A Randomized Trial of an Eight-Week, Once Weekly Primaquine Regimen to Prevent Relapse of Plasmodium vivax in Northern Frontie Province, Pakistan.PLoS ONE www.plosone.org 8.
17. Manson J (1975) Patterns of Plasmodium vivax recurrence in a high-incidence coastal area of El Salvador, C.A. Am J Trop Med Hyg. 24:581-585.
18. Mendis K, Sina BJ, Marchesini P, Carter R (2001) The neglected burden of Plasmodium vivax malaria. Am J Trop Med Hyg. 64: 97-106.
19. Pukrittayakamee S, Imwong M, Looareesuwan S, White NJ (2004) Therapeutic responses to antimalarial and antibacterial drugs in vivax malaria. Acta Tropica. 89: 351-356.
20. Rowland M, Durrani N (1999) Randomized controlled trials of 5and 14-days primaquine therapy against relapses of vivax malaria in an Afghan refugee settlement in Pakistan. Trans R Soc Trop Med Hyg. 93: 641-643.
21. Wernsdorfer WH (1988) Principles and practice of malariology. Churchill Livingstone, London.
22. Zakeri S, Barjesteh H, Djadid N (2006) Merozoite surface protein-3α is a reliable marker for population genetic of Plasmodium vivax. Malaria J. 5: 53-58.